777 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AZN Astrazeneca PLC $37.56 $95.16B Downtrend
Article Searches
Agios Rides on Tibsovo Approval Amid Reliance on Celgene http://www.zacks.com/stock/news/329504/agios-rides-on-tibsovo-approval-amid-reliance-on-celgene?cid=CS-ZC-FT-329504 Oct 19, 2018 - Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard http://www.zacks.com/research-daily/187244/top-analyst-reports-for-astrazeneca-salesforce-mastercard?cid=CS-ZC-FT-187244 Oct 18, 2018 - Top Analyst Reports for AstraZeneca, Salesforce & Mastercard
Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market http://www.zacks.com/stock/news/328943/mercks-keytruda-on-a-roll-in-a-thriving-anti-pd-l1-market?cid=CS-ZC-FT-328943 Oct 18, 2018 - Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
Stocks making the biggest move premarket: MS, GS, UNH, JNJ, WMT & more https://www.cnbc.com/2018/10/16/stocks-making-the-biggest-move-premarket-ms-gs-unh-jnj-wmt--more.html Oct 16, 2018 - Names on the move ahead of the open.
Healthcare 16-24% Target Net Gains Pace WallStars For October https://seekingalpha.com/article/4211623-healthcare-16minus-24-percent-target-net-gains-pace-wallstars-october?source=feed_all_articles Oct 15, 2018 - Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides.The Healthcare sector is comprised of 1
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion http://www.zacks.com/stock/news/327731/jj-jnj-gets-fda-approval-for-xarelto-label-expansion?cid=CS-ZC-FT-327731 Oct 12, 2018 - Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts http://www.zacks.com/stock/news/327579/merrimack-mack-focuses-on-early-stage-pipeline-and-cost-cuts?cid=CS-ZC-FT-327579 Oct 11, 2018 - Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
Altimmune Declines Too Much https://seekingalpha.com/article/4210760-altimmune-declines-much?source=feed_sector_healthcare Oct 09, 2018 - Altimmune, Inc. is a clinical stage immunotherapeutics company developing robust and durable immune responses intended for the prevention and treatment of several illnesses.The market is too pessimist
Top Research Reports for JPMorgan, American Express & FedEx http://www.zacks.com/research-daily/185837/top-research-reports-for-jpmorgan-american-express-fedex?cid=CS-ZC-FT-185837 Oct 09, 2018 - Top Research Reports for JPMorgan, American Express & FedEx
Lexicon Likely Looking At Even More Competition In Type 1 Diabetes https://seekingalpha.com/article/4210037-lexicon-likely-looking-even-competition-type-1-diabetes?source=feed_tag_editors_picks Oct 05, 2018 - Data from Phase III trials of Lilly/Boehringer's Jardiance in Type 1 diabetes supports submission and commercialization, bringing another competitor into the market.Lexicon's sotagliflozin is not out

Pages: 123456...78

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GSK GlaxoSmithKline PLC NYSE $39.21 $97.25B
BMY Bristol-Myers Squibb Company NYSE $61.3 $100.03B
SNY Sanofi NYSE $43.75 $109.14B
LLY Eli Lilly and Company NYSE $105.71 $113.53B
NVO Novo Nordisk A/S NYSE $47.64 $114.84B
Sector: Health Care > Industry: Major Pharmaceuticals
DeepLinks for Astrazeneca PLC